Biotechnology Industry Organization (BIO) President & CEO James Greenwood Named as Plenary Speaker for 2007 Mid-Atlantic Bio Conference.Joins Nobel Laureate Noun 1. Nobel Laureate - winner of a Nobel prize Nobelist laureate - someone honored for great achievements; figuratively someone crowned with a laurel wreath Dr. Thomas Cech Thomas Robert Cech (December 8, 1947 in Chicago) is a Nobel Laureate in chemistry. He grew up in Iowa City, Iowa. In 1966, he entered Grinnell College where he obtained a B.A. in 1970. In 1975, Cech completed his Ph.D. , AstraZeneca CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David Brennan and Biogen Idec Chairman & CEO James Mullen BETHESDA, Md. -- James C. Greenwood James Charles (Jim) Greenwood (born May 4, 1951) represented Pennsylvania's Eighth Congressional District for six terms in the United States House of Representatives as a Republican. Greenwood was born in Philadelphia, Pennsylvania and grew up in Holland, Pennsylvania. , President and CEO of the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
MAVA Minnesota Association for Volunteer Administration MAVA Martin Van Buren National Historic Site (US National Park Service) MAVA Massachusetts Association of Vocational Administrators ), and the Virginia Biotechnology Association The Virginia Biotechnology Association (VaBIO) is the statewide trade group that promotes the scientific and economic impact of the biotechnology industry in the Commonwealth of Virginia. (VaBIO). Mr. Greenwood will join a world-class lineup of keynote speakers, including Nobel Laureate Dr. Thomas Cech, president of the Howard Hughes Medical Institute Howard Hughes Medical Institute, (HHMI), nonprofit medical research organization founded in 1953 by Howard Hughes and largly funded from proceeds of the 1984–85 sale of Hughes Aircraft. Headquartered in Chevy Chase, Md. , David Brennan, CEO of AstraZeneca, and James Mullen, Chairman and CEO of Biogen Idec. James Greenwood is scheduled to speak on Thursday morning, October 25th. On Friday, October 26th, Thomas Cech, David Brennan and James Mullen will deliver plenary and closing luncheon addresses. In addition to keynote addresses, 2007 Mid-Atlantic Bio's panel discussions will explore topics such as: * What's hot and what's not in medical devices * Recent advances in science, translation into product development and definition of specific regulatory requirements for clinical assessment * Cases, decisions, and legislation which may affect bioscience moving forward * Some of the recent advances and opportunities in biodefense and pandemic pandemic /pan·dem·ic/ (pan-dem´ik) 1. a widespread epidemic of a disease. 2. widely epidemic. pan·dem·ic adj. Epidemic over a wide geographic area. n. research * Recent M&A activity and lessons learned from recent transactions in the mid-Atlantic region * Biotech strategies that combat climate change and positively impact the Earth * Innovative business models, IP, and strategies for commercializing biomarker research * Trends in regulations across federal agencies See www.MidAtlanticBio.org for a complete program agenda. A sampling of featured panelists and speakers include such notable figures in bioscience as: * Mario Brossi, Senior Representative for North America, Swiss Foreign Investment Agency * Daryl Falkner, CEO, Digene * Paul Fisher, President and CEO, Genvec * Russ Gantt, Vice President of Deal Management, AstraZeneca * Scott Gottlieb, Former Deputy Commissioner, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. * Carole Heilman, Director of the Division of Microbiology and Infectious Diseases, NIAID NIAID National Institute of Allergy and Infectious Diseases. * Lorence Kim, Co-Head of Biotech Investment Banking, Goldman Sachs * Michael Kurilla, Director, Office of Biodefense Research Affairs * Dr. Linda Magee, Director, Bionow, Warrington, UK * Jeffrey Matsuura, Technology Partnering Officer, Embassy of Canada * Randy Mills, President & CEO, Osiris * David Mott, CEO and President, MedImmune * Robert Power, Vice President, Global Corporate Client Group, New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. Euronext * Jeanne Riley, Senior Vice President and Chief Commercial Officer, ATCC ATCC American Type Culture Collection, see there * Andrew Thompson, CEO, Proteus Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. , Inc. * Sudhir Srivastava, Chief of the Cancer Biomarker Research Group at NCI's Early Detection Research Network 2007 Mid-Atlantic Bio will also host some of the areas most influential venture funds, who will offer advice on how to present to investors for funding, discuss differential product development costs here and abroad, and strategies for emerging companies and CEOs. Venture funds participating in 2007 Mid-Atlantic Bio include: * Anthem Capital * CIT n. 1. A citizen; an inhabitant of a city; a pert townsman; - used contemptuously. Which past endurance sting the tender cit. - Emerson. Gap Fund * Harbert Venture Partners * H.I.G. Ventures * Intersouth Partners * New Enterprise Associates * Oxford Finance Corporation * The Carlyle Group About Mid-Atlantic Bio Mid-Atlantic Bio is the only regional event to combine components of an industry convention and investor conference under one roof. Co-hosted by MdBio/Tech Council of Maryland, the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO), the initiative benefits from broad regional support, including the investor and greater business communities, academic institutions, government agencies, and partnered regional associations. The event aims to bring together a critical mass of public and private stakeholders, including biotechnology and pharmaceutical senior executives, scientists and researchers, academia, policy makers, legislators, and venture capitalists to provide a premiere Mid-Atlantic networking and business development forum, leverage the region's world-renowned R&D resources and opportunities, and favorably position the region's biotechnology industry in terms of its collective strengths, resources and competencies among key constituencies. For more on the Mid-Atlantic Bio Conference, complete program agenda and speaker information, as well as registration information, please visit www.MidAtlanticBio.org. About MdBio/Tech Council of Maryland MdBio/Tech Council of Maryland is a private non-profit trade association with a mission to promote the growth and quality of the life sciences and technology communities in Maryland and the region. For more information, please visit www.techcouncilmd.com. About MAVA Founded in 1986, MAVA represents the collective interests of venture capitalists investing in the mid-Atlantic, including more than 500+ venture professionals, at 125 firms, with more than $90 Billion in capital under management. For more information, please visit www.mava.org. About VaBIO VaBIO, the Virginia Biotechnology Association, is the 200-member statewide trade group that promotes the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. For more information, visit www.vabio.org. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion